In our in vitro experiments in EC human cells (OE19), the combination of HER-1-418 (cetuximab-like) and HER-2-266 (pertuzumab-like) or HER-2-597 (trastuzumab-like) peptide mimics or peptide vaccine antibodies demonstrated superior anti-tumor responses over single treatment. The gene discussed is EGFR; the disease is neoplasm.